Triple-Negative Breast Cancer Clinical Trial:A Potential Treatment Option for You
Triple-negative breast cancer (TNBC) has limited available treatment options, especially for patients who still have cancer in their breast and/or lymph nodes after pre-operative treatment. The TROPION-Breast03 study is looking to improve treatment options for such patients.
Step 1
Find a research site nearby. This study prioritizes patient needs, starting with convenient locations to receive care.
Step 2
Fill out the pre-screener form. Time is precious – patients fill out this brief online form to determine initial eligibility upfront.
Which patients are eligible for this triple-negative breast cancer clinical trial?
The TROPION-Breast03 study is looking for individuals who:
- Are at least 18 years old
- Have been diagnosed with Stage 1-3 triple-negative breast cancer
- Still have cancer cells after treatment to try to shrink their cancer before surgery (neoadjuvant therapy), either in their breast or lymph node(s) under their arm
- Have had at least 6 cycles of treatment before surgery
- Have no known BRCA1 or BRCA2 mutation
In addition, patients must meet certain criteria, as determined during the screening process, in order to participate in this triple-negative breast cancer study.
Loading map ...
